> top > docs > PubMed:24121271 > annotations

PubMed:24121271 JSONTXT

Annnotations TAB JSON ListView MergeView

c_corpus

Id Subject Object Predicate Lexical cue
T1 4-18 D012175 denotes retinoblastoma
T2 4-18 D012175 denotes retinoblastoma
T3 19-24 D009369 denotes tumor
T4 19-24 D009369 denotes tumor
T5 19-35 GO:0051726 denotes tumor suppressor
T6 19-35 GO:0008181 denotes tumor suppressor
T7 36-43 CHEBI:34922 denotes pathway
T10 74-79 PR:P70424 denotes ErbB2
T11 74-79 PR:P06494 denotes ErbB2
T12 74-79 PR:P04626 denotes ErbB2
T13 74-79 PR:000002082 denotes ErbB2
T14 89-95 UBERON:0000310 denotes breast
T15 89-102 D001943 denotes breast cancer
T16 89-102 D001943 denotes breast cancer
T17 108-117 UBERON:0004529 denotes processes
T20 150-174 D002285 denotes ductal carcinoma in situ
T21 150-174 D002285 denotes ductal carcinoma in situ
T27 176-180 CVCL_5552 denotes DCIS
T26 176-180 D002285 denotes DCIS
T28 176-180 D002285 denotes DCIS
T29 194-200 UBERON:0000310 denotes breast
T30 194-207 D001943 denotes breast cancer
T31 194-207 D001943 denotes breast cancer
T32 234-250 UBERON:0000021 denotes Epidermal growth
T36 234-257 GO:0005154 denotes Epidermal growth factor
T37 234-266 Q01279 denotes Epidermal growth factor receptor
T38 234-266 P0CY46 denotes Epidermal growth factor receptor
T39 234-266 P55245 denotes Epidermal growth factor receptor
T40 234-266 P00533 denotes Epidermal growth factor receptor
T41 234-266 P04412 denotes Epidermal growth factor receptor
T43 234-266 P13387 denotes Epidermal growth factor receptor
T44 234-266 PR:000006933 denotes Epidermal growth factor receptor
T42 234-266 D066246 denotes Epidermal growth factor receptor
T52 270-275 PR:P70424 denotes ErbB2
T53 270-275 PR:P06494 denotes ErbB2
T54 270-275 PR:P04626 denotes ErbB2
T55 270-275 PR:000002082 denotes ErbB2
T57 305-309 CVCL_5552 denotes DCIS
T56 305-309 D002285 denotes DCIS
T58 305-309 D002285 denotes DCIS
T59 335-349 D012175 denotes retinoblastoma
T60 335-349 D012175 denotes retinoblastoma
T61 350-355 D009369 denotes tumor
T62 350-355 D009369 denotes tumor
T63 350-366 GO:0051726 denotes tumor suppressor
T64 350-366 GO:0008181 denotes tumor suppressor
T65 372-379 CHEBI:34922 denotes pathway
T66 415-421 PR:Q54JW9 denotes impact
T67 415-421 PR:Q642J4 denotes impact
T70 425-430 PR:P70424 denotes ErbB2
T71 425-430 PR:P06494 denotes ErbB2
T72 425-430 PR:P04626 denotes ErbB2
T73 425-430 PR:000002082 denotes ErbB2
T76 464-483 D018450 denotes disease progression
T77 464-483 D018450 denotes disease progression
T78 517-527 SO:1000029 denotes deficiency
T79 558-567 CHEBI:25367 denotes molecules
T80 612-627 CL:0000066 denotes epithelial cell
T81 612-641 GO:0090136 denotes epithelial cell-cell adhesion
T84 678-714 GO:0001837 denotes epithelial-to-mesenchymal transition
T85 704-714 SO:1000009 denotes transition
T89 716-719 GO:0001837 denotes EMT
T86 716-719 PR:000014990 denotes EMT
T87 716-719 O75751 denotes EMT
T88 716-719 PR:000002111 denotes EMT
T91 716-719 PR:Q03526 denotes EMT
T92 716-719 PR:Q08881 denotes EMT
T90 716-719 UBERON:0014912 denotes EMT
T95 763-768 PR:P70424 denotes ErbB2
T96 763-768 PR:P06494 denotes ErbB2
T97 763-768 PR:P04626 denotes ErbB2
T98 763-768 PR:000002082 denotes ErbB2
T100 929-933 CVCL_5552 denotes DCIS
T99 929-933 D002285 denotes DCIS
T101 929-933 D002285 denotes DCIS
T104 1031-1036 PR:P70424 denotes ErbB2
T105 1031-1036 PR:P06494 denotes ErbB2
T106 1031-1036 PR:P04626 denotes ErbB2
T107 1031-1036 PR:000002082 denotes ErbB2
T109 1082-1085 CVCL_R774 denotes CDK
T110 1082-1085 GO:0004693 denotes CDK
T117 1082-1088 Q9XTR1 denotes CDK4/6
T118 1141-1147 CHEBI:34935 denotes cohort
T120 1151-1155 CVCL_5552 denotes DCIS
T119 1151-1155 D002285 denotes DCIS
T121 1151-1155 D002285 denotes DCIS
T124 1205-1210 PR:P70424 denotes ErbB2
T125 1205-1210 PR:P06494 denotes ErbB2
T126 1205-1210 PR:P04626 denotes ErbB2
T127 1205-1210 PR:000002082 denotes ErbB2
T129 1262-1266 CVCL_5552 denotes DCIS
T128 1262-1266 D002285 denotes DCIS
T130 1262-1266 D002285 denotes DCIS
T131 1267-1277 D012008 denotes recurrence
T132 1267-1277 D012008 denotes recurrence
T133 1329-1336 D004194 denotes disease
T134 1329-1336 D004194 denotes disease
T137 1362-1367 PR:P70424 denotes ErbB2
T138 1362-1367 PR:P06494 denotes ErbB2
T139 1362-1367 PR:P04626 denotes ErbB2
T140 1362-1367 PR:000002082 denotes ErbB2
T142 1377-1381 CVCL_5552 denotes DCIS
T141 1377-1381 D002285 denotes DCIS
T143 1377-1381 D002285 denotes DCIS
T144 1436-1442 UBERON:0000310 denotes breast
T145 1436-1449 D001943 denotes breast cancer
T146 1436-1449 D001943 denotes breast cancer
T147 1512-1519 CHEBI:34922 denotes pathway
T148 1548-1554 UBERON:0000310 denotes breast
T149 1548-1560 D001943 denotes breast tumor
T150 1548-1560 D001943 denotes breast tumor
T154 1649-1653 CVCL_5552 denotes DCIS
T153 1649-1653 D002285 denotes DCIS
T155 1649-1653 D002285 denotes DCIS
T156 1666-1673 D004194 denotes disease
T157 1666-1673 D004194 denotes disease

DisGeNET

Id Subject Object Predicate Lexical cue
T0 1205-1210 gene:2064 denotes ErbB2
T1 1267-1277 disease:C1458156 denotes recurrence
T2 1205-1210 gene:2064 denotes ErbB2
T3 1151-1155 disease:C0007124 denotes DCIS
T4 1205-1210 gene:2064 denotes ErbB2
T5 1262-1266 disease:C0007124 denotes DCIS
T6 1362-1367 gene:2064 denotes ErbB2
T7 1427-1449 disease:C0853879 denotes invasive breast cancer
R1 T0 T1 associated_with ErbB2,recurrence
R2 T2 T3 associated_with ErbB2,DCIS
R3 T4 T5 associated_with ErbB2,DCIS
R4 T6 T7 associated_with ErbB2,invasive breast cancer

PubmedHPO

Id Subject Object Predicate Lexical cue
T1 194-207 HP_0003002 denotes breast cancer
T2 194-207 HP_0100013 denotes breast cancer
T3 201-207 HP_0002664 denotes cancer
T4 335-349 HP_0009919 denotes retinoblastoma
T5 350-355 HP_0002664 denotes tumor
T6 1046-1052 HP_0002664 denotes cancer
T7 1436-1449 HP_0003002 denotes breast cancer
T8 1436-1449 HP_0100013 denotes breast cancer
T9 1443-1449 HP_0002664 denotes cancer
T10 1548-1560 HP_0003002 denotes breast tumor
T11 1548-1560 HP_0100013 denotes breast tumor
T12 1555-1560 HP_0002664 denotes tumor

Allie

Id Subject Object Predicate Lexical cue
SS1_24121271_1_0 150-174 expanded denotes ductal carcinoma in situ
SS2_24121271_1_0 176-180 abbr denotes DCIS
SS1_24121271_2_0 335-366 expanded denotes retinoblastoma tumor suppressor
SS2_24121271_2_0 368-370 abbr denotes RB
SS1_24121271_4_0 678-714 expanded denotes epithelial-to-mesenchymal transition
SS2_24121271_4_0 716-719 abbr denotes EMT
AE1_24121271_1_0 SS1_24121271_1_0 SS2_24121271_1_0 abbreviatedTo ductal carcinoma in situ,DCIS
AE1_24121271_2_0 SS1_24121271_2_0 SS2_24121271_2_0 abbreviatedTo retinoblastoma tumor suppressor,RB
AE1_24121271_4_0 SS1_24121271_4_0 SS2_24121271_4_0 abbreviatedTo epithelial-to-mesenchymal transition,EMT

UseCases_ArguminSci_Discourse

Id Subject Object Predicate Lexical cue
T1 0-103 DRI_Unspecified denotes The retinoblastoma tumor suppressor pathway modulates the invasiveness of ErbB2-positive breast cancer.
T2 104-233 DRI_Background denotes The processes that control the progression of ductal carcinoma in situ (DCIS) to invasive breast cancer remain poorly understood.
T3 234-380 DRI_Outcome denotes Epidermal growth factor receptor 2 (ErbB2) overexpression is common in DCIS, as is disruption of the retinoblastoma tumor suppressor (RB) pathway.
T4 381-484 DRI_Approach denotes Here, we examined the cooperative impact of ErbB2 and RB deregulation on facets of disease progression.
T5 485-721 DRI_Outcome denotes Our studies demonstrate that RB deficiency altered the expression of key molecules needed for proper cellular organization and epithelial cell-cell adhesion as part of a program related to the epithelial-to-mesenchymal transition (EMT).
T6 722-821 DRI_Outcome denotes An increase in the invasive potential of ErbB2-overexpressing cells was observed upon RB depletion.
T7 822-983 DRI_Outcome denotes Further, stable knockdown of RB resulted in invasive lesions in orthotopic xenograft assays, compared with DCIS-like lesions developing from RB-proficient cells.
T8 984-1126 DRI_Outcome denotes Conversely, the invasive phenotype observed in ErbB2-positive cancer models was inhibited through CDK4/6 inhibition in an RB-dependent manner.
T9 1127-1337 DRI_Unspecified denotes Finally, in a cohort of DCIS cases, we show that, although elevated levels of ErbB2 are associated with increased risk of a subsequent DCIS recurrence, it is not associated with progression to invasive disease.
T10 1338-1450 DRI_Background denotes In contrast, RB loss in ErbB2-positive DCIS cases was associated with increased risk for invasive breast cancer.
T11 1451-1674 DRI_Approach denotes Taken together, these data demonstrate a key role for the RB pathway in invasion associated with breast tumor progression, and shed light on the key molecular events that promote the progression of DCIS to invasive disease.

PubMed_ArguminSci

Id Subject Object Predicate Lexical cue
T1 104-233 DRI_Background denotes The processes that control the progression of ductal carcinoma in situ (DCIS) to invasive breast cancer remain poorly understood.
T2 234-380 DRI_Outcome denotes Epidermal growth factor receptor 2 (ErbB2) overexpression is common in DCIS, as is disruption of the retinoblastoma tumor suppressor (RB) pathway.
T3 381-484 DRI_Approach denotes Here, we examined the cooperative impact of ErbB2 and RB deregulation on facets of disease progression.
T4 485-721 DRI_Outcome denotes Our studies demonstrate that RB deficiency altered the expression of key molecules needed for proper cellular organization and epithelial cell-cell adhesion as part of a program related to the epithelial-to-mesenchymal transition (EMT).
T5 722-821 DRI_Outcome denotes An increase in the invasive potential of ErbB2-overexpressing cells was observed upon RB depletion.
T6 822-983 DRI_Outcome denotes Further, stable knockdown of RB resulted in invasive lesions in orthotopic xenograft assays, compared with DCIS-like lesions developing from RB-proficient cells.
T7 984-1126 DRI_Outcome denotes Conversely, the invasive phenotype observed in ErbB2-positive cancer models was inhibited through CDK4/6 inhibition in an RB-dependent manner.
T8 1338-1450 DRI_Background denotes In contrast, RB loss in ErbB2-positive DCIS cases was associated with increased risk for invasive breast cancer.
T9 1451-1674 DRI_Approach denotes Taken together, these data demonstrate a key role for the RB pathway in invasion associated with breast tumor progression, and shed light on the key molecular events that promote the progression of DCIS to invasive disease.

DisGeNET5_gene_disease

Id Subject Object Predicate Lexical cue
24121271-0#74#79#gene2064 1031-1036 gene2064 denotes ErbB2
24121271-0#89#102#diseaseC0006142 1068-1242 diseaseC0006142 denotes bited through CDK4/6 inhibition in an RB-dependent manner. Finally, in a cohort of DCIS cases, we show that, although elevated levels of ErbB2 are associated with increased r
24121271-0#89#102#diseaseC0678222 1068-1242 diseaseC0678222 denotes bited through CDK4/6 inhibition in an RB-dependent manner. Finally, in a cohort of DCIS cases, we show that, although elevated levels of ErbB2 are associated with increased r
24121271-2#0#32#gene1956 234-266 gene1956 denotes Epidermal growth factor receptor
24121271-2#36#41#gene2064 270-275 gene2064 denotes ErbB2
24121271-2#71#75#diseaseC0007124 305-309 diseaseC0007124 denotes DCIS
24121271-2#101#115#diseaseC0035335 335-349 diseaseC0035335 denotes retinoblastoma
24121271-9#24#29#gene2064 1362-1367 gene2064 denotes ErbB2
24121271-9#39#43#diseaseC0007124 1377-1381 diseaseC0007124 denotes DCIS
24121271-9#89#111#diseaseC0853879 1427-1449 diseaseC0853879 denotes invasive breast cancer
74#79#gene206489#102#diseaseC0006142 24121271-0#74#79#gene2064 24121271-0#89#102#diseaseC0006142 associated_with ErbB2,"bited through CDK4/6 inhibition in an RB-dependent manner. Finally, in a cohort of DCIS cases, we show that, although elevated levels of ErbB2 are associated with increased r"
74#79#gene206489#102#diseaseC0678222 24121271-0#74#79#gene2064 24121271-0#89#102#diseaseC0678222 associated_with ErbB2,"bited through CDK4/6 inhibition in an RB-dependent manner. Finally, in a cohort of DCIS cases, we show that, although elevated levels of ErbB2 are associated with increased r"
0#32#gene195671#75#diseaseC0007124 24121271-2#0#32#gene1956 24121271-2#71#75#diseaseC0007124 associated_with Epidermal growth factor receptor,DCIS
0#32#gene1956101#115#diseaseC0035335 24121271-2#0#32#gene1956 24121271-2#101#115#diseaseC0035335 associated_with Epidermal growth factor receptor,retinoblastoma
36#41#gene206471#75#diseaseC0007124 24121271-2#36#41#gene2064 24121271-2#71#75#diseaseC0007124 associated_with ErbB2,DCIS
36#41#gene2064101#115#diseaseC0035335 24121271-2#36#41#gene2064 24121271-2#101#115#diseaseC0035335 associated_with ErbB2,retinoblastoma
24#29#gene206439#43#diseaseC0007124 24121271-9#24#29#gene2064 24121271-9#39#43#diseaseC0007124 associated_with ErbB2,DCIS
24#29#gene206489#111#diseaseC0853879 24121271-9#24#29#gene2064 24121271-9#89#111#diseaseC0853879 associated_with ErbB2,invasive breast cancer